Trial Profile
A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Jul 2023 Status changed from active, no longer recruiting to completed.
- 14 Dec 2022 Planned End Date changed from 30 Dec 2022 to 30 Jun 2023.
- 27 Sep 2022 Results developing a PK/PD model to optimize dose anddosing schedule for PARPi and paclitaxel combination to mitigate treatment-associated neutropenia events, presented at the 2022 American College of Clinical Pharmacology Annual Meeting